Banner Publications MH200828 N141

Publications

Results found: 250

Showing results: 1 - 50

Nature

Publisher Correction: Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-09-2022
Key
Molecular cell

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

18-11-2021
Key
Nature genetics

Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

01-01-2021
Key
British journal of cancer

Ductal carcinoma in situ: to treat or not to treat, that is the question.

01-08-2019
Key
Nature

Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis.

01-08-2019
Key
Nature cell biology

Therapeutic targeting of macrophages enhances chemotherapy efficacy by unleashing type I interferon response.

01-04-2019
Key
Nature reviews. Cancer

Learning to distinguish progressive and non-progressive ductal carcinoma in situ.

01-12-2022
Nature communications

MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling.

02-11-2022
Nature

Truncated FGFR2 is a clinically actionable oncogene in multiple cancers.

01-08-2022
Cancers

Epithelial-to-Mesenchymal Transition Drives Invasiveness of Breast Cancer Brain Metastases.

25-06-2022
Breast cancer research : BCR

Combined inhibition of EZH2 and ATM is synthetic lethal in BRCA1-deficient breast cancer.

17-06-2022
Molecular & cellular oncology

Filling in the gaps in PARP inhibitor-induced synthetic lethality.

15-04-2022
STAR protocols

Functional genetic dropout screens and in vivo validation of candidate therapeutic targets using mouse mammary tumoroids.

18-03-2022
Cancer research

A Microfluidic Cancer-on-Chip Platform Predicts Drug Response Using Organotypic Tumor Slice Culture.

01-02-2022
Cancer research

A BRCA1 Coiled-Coil Domain Variant Disrupting PALB2 Interaction Promotes the Development of Mammary Tumors and Confers a Targetable Defect in Homologous Recombination Repair.

15-12-2021
Nature reviews. Clinical oncology

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.

01-12-2021
Cancers

Atlas of Lobular Breast Cancer Models: Challenges and Strategic Directions.

27-10-2021
Molecular cell

Replication gaps are a key determinant of PARP inhibitor synthetic lethality with BRCA deficiency.

05-08-2021
Cancers

PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.

18-07-2021
Nature communications

Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer.

16-07-2021
Nature genetics

Author Correction: Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts.

01-05-2021
Science advances

SMARCAD1-mediated active replication fork stability maintains genome integrity.

01-05-2021
Molecular & cellular proteomics : MCP

Feasibility of Phosphoproteomics on Leftover Samples After RNA Extraction With Guanidinium Thiocyanate.

06-04-2021
Cancers

Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.

22-03-2021
Current opinion in genetics & development

The use of CRISPR/Cas9-based gene editing strategies to explore cancer gene function in mice.

01-02-2021
Annals of oncology : official journal of the European Society for Medical Oncology

ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.

01-12-2020
Nat. Commun: Nature Communications

Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

30-11-2020
Nat. Commun: Nature Communications

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

21-09-2020
Current biology : CB

How the COVID-19 pandemic highlights the necessity of animal research.

21-09-2020
Clinical cancer research : an official journal of the American Association for Cancer Research

Functional Categorization of BRCA1 Variants of Uncertain Clinical Significance in Homologous Recombination Repair Complementation Assays.

01-09-2020
Nat Commun.

Sex differences in oncogenic mutational processes

28-08-2020
Cell reports

Functional Radiogenetic Profiling Implicates ERCC6L2 in Non-homologous End Joining.

25-08-2020
Oncotarget

Correction: Neoadjuvant olaparib targets hypoxia to improve radioresponse in a homologous recombination-proficient breast cancer model.

28-04-2020
Cancer research

Truncated ASPP2 Drives Initiation and Progression of Invasive Lobular Carcinoma via Distinct Mechanisms.

01-04-2020
Oncoimmunology

Response of metastatic mouse invasive lobular carcinoma to mTOR inhibition is partly mediated by the adaptive immune system.

03-03-2020
The EMBO journal

In situ CRISPR-Cas9 base editing for the development of genetically engineered mouse models of breast cancer.

02-03-2020
Science translational medicine

BRCAness, SLFN11, and RB1 loss predict response to topoisomerase I inhibitors in triple-negative breast cancers.

19-02-2020
Nat: Nature

Pan-cancer analysis of whole genomes

05-02-2020
Genes & development

TRPS1 acts as a context-dependent regulator of mammary epithelial cell growth/differentiation and breast cancer development.

01-02-2020
Journal of mammary gland biology and neoplasia

Exogenous ERα Expression in the Mammary Epithelium Decreases Over Time and Does Not Contribute to p53-Deficient Mammary Tumor Formation in Mice.

01-12-2019
Journal of mammary gland biology and neoplasia

GATA3 Truncating Mutations Promote Cistromic Re-Programming In Vitro, but Not Mammary Tumor Formation in Mice.

01-09-2019
Nature communications

Rebalancing of actomyosin contractility enables mammary tumor formation upon loss of E-cadherin.

23-08-2019
Clinical cancer research : an official journal of the American Association for Cancer Research

EZH2 Is Overexpressed in BRCA1-like Breast Tumors and Predictive for Sensitivity to High-Dose Platinum-Based Chemotherapy.

15-07-2019
Cancer discovery

PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.

01-06-2019
The EMBO journal

Long-term expanding human airway organoids for disease modeling.

15-02-2019
Cancer research

Radiosensitivity Is an Acquired Vulnerability of PARPi-Resistant BRCA1-Deficient Tumors.

01-02-2019
Nature

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

01-02-2019
Nature communications

Comparative oncogenomics identifies combinations of driver genes and drug targets in BRCA1-mutated breast cancer.

23-01-2019
Nature communications

The ASCIZ-DYNLL1 axis promotes 53BP1-dependent non-homologous end joining and PARP inhibitor sensitivity.

17-12-2018
EMBO molecular medicine

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.

01-12-2018

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.